In addition, we identified, albeit rarely, potentially targetable alterations, such as IDH1 or ERBB2 mutations or MMRd/MSI, in such aggressive cancers, most of which (80%) were associated with Crohn disease. This evidence concerns the gene ERBB2 and cancer.